Testing a new drug for hard-to-control seizures in tuberous sclerosis complex
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study tests an investigational drug called AV078 for people with tuberous sclerosis complex (TSC) whose seizures are not controlled by at least two current medications. The goal is to see if AV078 can reduce seizure frequency safely, and participants continue their usual seizure medications during the trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years old or older.
- You must have a diagnosis of tuberous sclerosis complex (TSC), a condition that causes benign tumors and can lead to seizures.
- Your seizures must not be well controlled even after trying at least two different seizure medications.
- Your seizure medication doses must have been stable (no changes) for at least 4 weeks before the study starts, and you must be willing to keep them stable during the study.
- You cannot have had an infection requiring antibiotics in the past 4 weeks, or have had recent major surgery (including epilepsy surgery) or plan to have surgery during the study.
- You cannot be taking certain other medicines (like drugs that work similarly to the study drug, or drugs that suppress your immune system) that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether rapamycin (compared with a placebo) can reduce seizures caused by tuberous sclerosis complex (TSC) that have not been controlled by usual medicines. If you qualify, you may be helping doctors find a safer and more effective option for seizure control.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This Phase 2 study tests whether sirolimus (a targeted medicine) can stop or slow the start of seizures in very young babies diagnosed with tuberous sclerosis complex (TSC). If seizures are prevented early, it may also help protect early brain development.
This study tests a new medicine called SIF001 for safety. It first gives the medicine to healthy volunteers, and then to people with epilepsy who have seizures even while on their current medicines. The goal is to find a safe dose.
This trial tests whether a type of magnetic brain stimulation can reduce seizures in people with epilepsy that isn't helped by current treatments. It uses a non-invasive method that may offer a new option for controlling seizures.
This study tests a personalized, non-invasive brain stimulation method called tDCS for people with drug-resistant epilepsy that starts in one part of the brain. It aims to reduce seizures in those who cannot have surgery or have not been helped by surgery.
Hear when a new Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.